Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDT-10013 · 1 trial · 1 indication
Summed pain intensity is a time-weighted average pain score in numeric rating scale (NRS) over 1 to 48hrs (SPI-48). Summed pain intensity is calculated as area under the curve, using the trapezoidal rule to bridge adjacent time points. Specifically, NRS scores for two adjacent time points are averaged and then multiplied by the time span between points (in hours). The theoretical range for SPI-48 is 0 to 470, with lower scores indicative of less pain over this time period (i.e., lower scores are consistent with better analgesia). Time 0 was defined as the time the capsule was closed.
Similar to SPI-48, the theoretical range for this LOCF adjustment for rescue medication is 0-470, with lower scores indicative of less pain over this time period (i.e., lower scores are consistent with better analgesia). The calculation is identical to SPI-48 in terms of area-under the curve using the trapezoidal rule. However, the NRS score at the final assessment prior to rescue is carried forward through 48 hours, replacing the raw NRS scores post-rescue for each patient as applicable.
This sensitivity analysis is an integrated assessment of summed pain intensity over 1 to 48hrs (SPI-48) and total opioid intake (ME0-48) in first 48hrs. Briefly, subjects were ranked according to SPI-48 regardless of the treatment received (including Standard of Care, SOC). The mean of all the ranks for this variable was calculated. Then, the percent difference for each individual rank from the pooled mean rank was computed. This process was repeated for total opioid intake in the first 48hrs (ME0-48). The integrated endpoint for each subject was the sum of the rank order percent differences for SPI-48 and ME0-48. The theoretical minimum and maximum on the integrated endpoint are -197% and +197% in this study. Lower scores are better, indicative of less pain and/or less opioid intake.
Similar to SPI-48, the theoretical range for this WOCF adjustment for rescue medication is 0-470, with lower scores indicative of less pain over this time period (i.e., lower scores are consistent with better analgesia). The calculation is identical in terms of area-under the curve using the trapezoidal rule. However, the NRS score at the final assessment prior to each instance of rescue medication is carried forward through for a window based on the approximate half-life of the drug, replacing the raw NRS scores post-rescue for each patient until the end of the pharmacological activity window, at which point calculations revert to raw NRS as applicable. Note that WOCF SPI-48 may include multiple adjustment windows for each patient, depending on the number or rescue events and the active life of the medication selected.
| Arm | Type | Description |
|---|---|---|
| MDT-10013 | EXPERIMENTAL | Subjects will receive MDT-10013. |
| Standard of Care | ACTIVE_COMPARATOR | Subjects will receive standard of care. |
| Name | Type | Description |
|---|---|---|
| MDT-10013 | DRUG | - |
| Standard of care for pain | DRUG | - |
Inclusion Criteria: 1. Is male or female aged 18 to 80 years. 2. Has a body mass index from 18 kg/m2 to 40 kg/m2. 3. Is scheduled to undergo primary, unilateral, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures. 4. Is classified by American So...
MDT-10013 is an investigational small molecule being developed for the treatment of postoperative pain. It was studied in a Phase 2 clinical trial for acute postoperative pain following bunionectomy. The drug is not approved and remains in clinical development.
MDT-10013 is being developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker symbol MDT. The company conducted a Phase 2 trial of the drug in the United States.
MDT-10013 is in Phase 2 clinical development. A Phase 2 trial of the drug for postoperative pain has been completed. The drug is investigational and has not been approved by regulatory authorities.
MDT-10013 has one completed clinical trial, registered as NCT02077140. The study was a Phase 2, randomized, double-blind, active-controlled trial evaluating the drug in 192 adults with acute postoperative pain following bunionectomy in the United States.
MDT-10013 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied for its ability to treat postoperative pain, though the exact mechanism of action is not publicly detailed.